Controlled release of hyaluronan oligomers from biodegradable polymeric microparticle carriers

被引:28
作者
Hedberg, EL
Shih, CK
Solchaga, LA
Caplan, AI
Mikos, AG
机构
[1] Rice Univ, Dept Bioengn, Houston, TX 77251 USA
[2] Case Western Reserve Univ, Dept Orthopaed, Sch Med, Cleveland, OH 44106 USA
[3] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[4] Case Western Reserve Univ, Dept Biol, Skeletal Res Ctr, Cleveland, OH 44106 USA
关键词
hyaluronan; polysaccharide; controlled release; microparticles; PLGA;
D O I
10.1016/j.jconrel.2004.08.020
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In the present study, biodegradable microparticles of blends of poly(DL-lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) were explored as a potential carrier for the controlled release of polysaccharide oligomers. To this end, hyaluronan (HY) oligomers of varying molecular weights were incorporated into PLGA/PEG microparticles. Using a two-level fractional factorial experimental design, four microparticle formulation parameters, the amount of PEG included in the microparticles, the initial HY loading of the microparticles, the molecular weight of HY, and the molecular weight of PLGA, were studied for their influence on the incorporation and in vitro release of HY over the period of 28 days. The entrapment efficiencies were found to range between 10 +/- 1% and 24 +/- 2% depending on the initial loading and the molecular weight of the HY oligomer used in the fabrication of the microparticles. The HY was released in a multiphasic fashion including an initial burst release, followed by two separate periods of linear release. The normalized cumulative mass released during the burst release ranged from 25.1 +/- 9.2% to 93.0 +/- 0.7% and was found to be significantly influenced by the initial HY loading, the HY molecular weight, and the PLGA molecular weight. The initial period of linear release lasted from day 1 to day 14 and displayed normalized cumulative rates of release form 0.1 +/- 0.01%/day to 1.4 +/- 0.2%/day. During this period, PEG content of the microparticles and HY molecular weight exerted the greatest influence on the rate of release. Finally, the second period of linear release lasted through the final time-point at day 28. Here, the normalized cumulative rate of release values ranged from 0.2 +/- 0.1%/day to 3.6 +/- 0.7%/day and were dependent on all formulation parameters studied. These results demonstrate the potential of PLGA/PEG blend microparticles for the controlled release of HY oligomers. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:257 / 266
页数:10
相关论文
共 24 条
[1]   Biodegradation and biocompatibility of PLA and PLGA microspheres [J].
Anderson, JM ;
Shive, MS .
ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24
[2]   Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid polyglycolic acid copolymers [J].
Athanasiou, KA ;
Niederauer, GG ;
Agrawal, CM .
BIOMATERIALS, 1996, 17 (02) :93-102
[3]  
Box GEP., 1978, Statistics for experimenters
[4]   Microparticles of poly(DL-lactic-co-glycolic acid)/poly(ethylene glycol) blends for controlled drug delivery [J].
Cleek, RL ;
Ting, KC ;
Eskin, SG ;
Mikos, AG .
JOURNAL OF CONTROLLED RELEASE, 1997, 48 (2-3) :259-268
[5]   Controlled release of an osteogenic peptide from injectable biodegradable polymeric composites [J].
Hedberg, EL ;
Tang, A ;
Crowther, RS ;
Carney, DH ;
Mikos, AG .
JOURNAL OF CONTROLLED RELEASE, 2002, 84 (03) :137-150
[6]   Poly(alpha-hydroxy acids): Carriers for bone morphogenetic proteins [J].
Hollinger, JO ;
Leong, K .
BIOMATERIALS, 1996, 17 (02) :187-194
[7]  
Isobe M, 1996, J BIOMED MATER RES, V32, P433
[8]   The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices [J].
Jain, RA .
BIOMATERIALS, 2000, 21 (23) :2475-2490
[9]   PARTIAL MODIFICATION OF THE CARBAZOLE METHOD OF BITTER AND MUIR FOR QUANTITATION OF HEXURONIC ACIDS [J].
KOSAKAI, M ;
YOSIZAWA, Z .
ANALYTICAL BIOCHEMISTRY, 1979, 93 (02) :295-298
[10]   DRUG DELIVERY SYSTEMS USING HYALURONAN AND ITS DERIVATIVES [J].
LARSEN, NE ;
BALAZS, EA .
ADVANCED DRUG DELIVERY REVIEWS, 1991, 7 (02) :279-293